HK1144684A1 - Igf-1 fusion polypeptides and therapeutic uses thereof igf-1 - Google Patents

Igf-1 fusion polypeptides and therapeutic uses thereof igf-1

Info

Publication number
HK1144684A1
HK1144684A1 HK10110734.8A HK10110734A HK1144684A1 HK 1144684 A1 HK1144684 A1 HK 1144684A1 HK 10110734 A HK10110734 A HK 10110734A HK 1144684 A1 HK1144684 A1 HK 1144684A1
Authority
HK
Hong Kong
Prior art keywords
igf
igf1
component
fusion
fusion polypeptides
Prior art date
Application number
HK10110734.8A
Other languages
English (en)
Chinese (zh)
Inventor
David J Glass
George D Yancopoulos
Daly Thomas J G
Nicholas J Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1144684A1 publication Critical patent/HK1144684A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
HK10110734.8A 2005-01-07 2010-11-18 Igf-1 fusion polypeptides and therapeutic uses thereof igf-1 HK1144684A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64222905P 2005-01-07 2005-01-07
US65658305P 2005-02-25 2005-02-25

Publications (1)

Publication Number Publication Date
HK1144684A1 true HK1144684A1 (en) 2011-03-04

Family

ID=42634965

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10110734.8A HK1144684A1 (en) 2005-01-07 2010-11-18 Igf-1 fusion polypeptides and therapeutic uses thereof igf-1

Country Status (13)

Country Link
US (4) US7396918B2 (xx)
EP (2) EP1833847B1 (xx)
JP (1) JP4988599B2 (xx)
AT (1) ATE517120T1 (xx)
AU (1) AU2006203882B2 (xx)
CA (1) CA2594023C (xx)
DK (1) DK2241575T3 (xx)
ES (1) ES2541810T3 (xx)
HK (1) HK1144684A1 (xx)
HU (1) HUE027645T2 (xx)
PL (2) PL1833847T3 (xx)
PT (1) PT2241575E (xx)
WO (1) WO2006074390A2 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
TWI427084B (zh) * 2006-06-09 2014-02-21 Novartis Ag 穩定化之類胰島素生長因子多肽
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
AU2007291501B2 (en) * 2006-08-31 2012-07-12 F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
GB0715213D0 (en) * 2007-08-06 2007-09-12 Asterlon Ltd Igf-1
DK2279210T3 (en) 2008-05-07 2017-07-24 Biomarin Pharm Inc Lysosomal targeting peptides and uses thereof
US8685403B2 (en) 2009-01-30 2014-04-01 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
US7963705B2 (en) * 2009-02-24 2011-06-21 Avago Technologies Fiber Ip (Singapore) Pte. Ltd. Molded interconnect device (MID) optical connector with metal retaining clip
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
CN102618575A (zh) * 2011-09-16 2012-08-01 江苏普罗赛生物技术有限公司 哺乳动物细胞大规模生产重组人IGF1-Fc融合蛋白的实验技术
CN104884467A (zh) * 2012-12-18 2015-09-02 诺华股份有限公司 在遗传修饰的哺乳动物细胞中生产治疗性蛋白质
LT2935320T (lt) * 2012-12-18 2019-11-11 Novartis Ag Stabilizuoti insulino tipo augimo faktoriaus polipeptidai
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
WO2015111008A2 (en) 2014-01-27 2015-07-30 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
WO2016115171A1 (en) * 2015-01-16 2016-07-21 The Regents Of The University Of California Insulin-like growth factor 2 (igf2) signaling and modulation
EP3865147A1 (en) 2015-10-02 2021-08-18 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
AU2017261216B2 (en) * 2016-05-06 2023-08-03 Immunoforge Co., Ltd. ELP fusion proteins for controlled and sustained release
EP3609522A4 (en) * 2017-04-10 2021-05-05 Yoram Palti METHODS AND COMPOUNDS FOR THE TREATMENT OF DIABETES
EP3453722A1 (en) * 2017-09-06 2019-03-13 Julius-Maximilians-Universität Würzburg Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase
CN113214410A (zh) * 2017-11-04 2021-08-06 海南大学 一种表达促皮质素与胰岛素样生长因子1融合蛋白的重组质粒、重组菌的构建方法
EP3569614A1 (en) * 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
US10821155B2 (en) * 2018-06-27 2020-11-03 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
CN115087458A (zh) * 2019-10-10 2022-09-20 阿米库斯治疗学公司 变体igf2构建体
US20220111011A1 (en) * 2020-10-13 2022-04-14 Betavive Ltd. Method and Compounds for Treating Diabetes and Associated Metabolic Diseases
WO2023214833A1 (ko) * 2022-05-04 2023-11-09 이뮤노포지 주식회사 Glp-1, 면역글로불린 fc, 및 igf-1을 포함하는 융합단백질 및 이의 용도
GB202216503D0 (en) * 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE69021335T2 (de) * 1989-06-09 1996-04-11 Gropep Pty. Ltd., Adelaide Wachstumshormonfusionsproteine.
IE912528A1 (en) 1990-07-19 1992-01-29 Scripps Clinic Res Inhabition of mac-1 receptor binding fibrinogen using d30¹homologs
AU4238493A (en) 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US6413740B1 (en) 1995-12-15 2002-07-02 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
AUPP298498A0 (en) 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
DK1141014T3 (da) * 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
WO2009015142A2 (en) 2007-07-23 2009-01-29 R.J.Reynolds Tobacco Company Smokeless tobacco compositions and methods for treating tobacco for use therein

Also Published As

Publication number Publication date
EP2241575B1 (en) 2015-06-24
US20060166328A1 (en) 2006-07-27
US8158581B2 (en) 2012-04-17
JP2008526233A (ja) 2008-07-24
CA2594023C (en) 2015-07-14
AU2006203882A1 (en) 2006-07-13
US20110020342A1 (en) 2011-01-27
EP2241575A1 (en) 2010-10-20
DK2241575T3 (en) 2015-08-24
PL2241575T3 (pl) 2015-12-31
PT2241575E (pt) 2015-09-16
ATE517120T1 (de) 2011-08-15
US20120195896A1 (en) 2012-08-02
US8445434B2 (en) 2013-05-21
US20090069235A1 (en) 2009-03-12
CA2594023A1 (en) 2006-07-13
WO2006074390A3 (en) 2007-01-11
US7396918B2 (en) 2008-07-08
US7837999B2 (en) 2010-11-23
WO2006074390A2 (en) 2006-07-13
ES2541810T3 (es) 2015-07-24
HUE027645T2 (en) 2016-10-28
EP1833847A2 (en) 2007-09-19
PL1833847T3 (pl) 2011-12-30
EP1833847B1 (en) 2011-07-20
JP4988599B2 (ja) 2012-08-01
AU2006203882B2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
HK1144684A1 (en) Igf-1 fusion polypeptides and therapeutic uses thereof igf-1
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
HK1149566A1 (en) Glp-1 analog fusion proteins
WO2005113606A3 (en) Fgf-21 fusion proteins
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
IL161016A (en) Polypeptides capable of ang-2 binding
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP1699920A4 (en) NEW RECOMBINANT PROTEINS WITH FREE N-TERMINAL THIOL
WO2004081026A3 (en) Polypeptides
WO2003058203A3 (en) Extended glucagon-like peptide-1 analogs
IL169820A0 (en) Amino acids with affinity for the alpha-2-delta-protein
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2008019368A3 (en) Albumin-insulin fusion proteins
CZ2014740A3 (xx)
WO2004078778A3 (en) PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
WO2006031370A3 (en) Polypeptide variants with altered effector function
WO2007035600A3 (en) Natriuretic activities
WO2007071692A3 (en) Immunogenic composition
WO2007047504A3 (en) Natriuretic peptide modified transferrin fusion proteins
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2005069726A3 (en) Hybrid and chimeric polypeptides that regulate activation of complement
WO2006049983A3 (en) Peptide yy modified transferrin fusion proteins
AP2006003544A0 (en) Amino acids with affinity for the alpha2delta-protein.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210103